Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.63 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.57 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.57 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 3/20 | 0.54 |
| ▸ | ULK1 | O75385 | 3/20 | 0.53 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387719 | 0.90 | TBK1 (0.70) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3389178 | 0.90 | TBK1 (0.59) | SYKTBK1CDK2MARK3BRD4 | |
| SCHEMBL3389438 | 0.89 | TBK1 (0.58) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3385828 | 0.88 | TBK1 (0.70) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3383911 | 0.88 | TBK1 (0.71) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3384653 | 0.86 | STK17A (0.60) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3385878 | 0.85 | ULK1 (0.70) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3384590 | 0.84 | ULK1 (0.74) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL3386277 | 0.84 | TBK1 (0.61) | SYKTBK1CDK2MARK3IKBKE | |
| SCHEMBL13431953 | 0.83 | TBK1 (0.83) | TBK1CDK2MARK3IKBKEBRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | SYK 627/4885TBK1 2898/4885CDK2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.